Monte Rosa Therapeutic (GLUE) Q1 2026 earnings summary

Executive summary

• Reported a net loss of $44.5 million for Q1 2026, compared to net income of $46.9 million in Q1 2025, reflecting a sharp decline in collaboration revenue and increased R&D and G&A expenses.

• Collaboration revenue dropped to $4.2 million from $84.9 million year-over-year, primarily due to timing of milestone payments from Roche and Novartis agreements.

• Advanced three clinical-stage programs toward Phase 2 trial initiations, with key readouts and study starts expected in 2026 and 2027.

• Interim clinical data for MRT-8102 showed rapid, deep, and durable reductions in systemic inflammation in subjects with elevated CVD risk.

• Strong cash position supports operations into 2029.

Financial highlights

• Research and development expenses increased to $44.1 million from $32.2 million year-over-year, driven by clinical and preclinical pipeline advancement and higher personnel costs.

• General and administrative expenses rose to $10.2 million from $8.7 million, reflecting increased personnel and professional service costs.

• Cash, cash equivalents, and marketable securities totaled $671.2 million as of March 31, 2026, up from $382.1 million at year-end 2025, mainly due to a $345 million public offering.

• Net cash used in operating activities was $37.4 million, with $261.0 million used in investing and $328.3 million provided by financing activities, mainly from a $323.8 million public offering.

• Net loss margin for Q1 2026 exceeds 100% due to negative operating income and low revenue.

Outlook and guidance

• Existing cash and marketable securities are expected to fund operations and capital requirements for at least the next 12 months and support the cash runway into 2029.

• Multiple Phase 2 studies for MRT-8102 and MRT-2359 are planned for 2026–2027, with key readouts expected in H2 2026 and 2027.

• IND submission for cyclin E1-directed MGD anticipated in H2 2026.

• Anticipates continued increases in R&D and G&A expenses as pipeline progresses and clinical trials expand.

• Additional funding will be sought through equity, debt, or collaborations to support future development and commercialization.